JP2021168647A - 病原体検出法 - Google Patents
病原体検出法 Download PDFInfo
- Publication number
- JP2021168647A JP2021168647A JP2021055249A JP2021055249A JP2021168647A JP 2021168647 A JP2021168647 A JP 2021168647A JP 2021055249 A JP2021055249 A JP 2021055249A JP 2021055249 A JP2021055249 A JP 2021055249A JP 2021168647 A JP2021168647 A JP 2021168647A
- Authority
- JP
- Japan
- Prior art keywords
- pathogen
- biological sample
- culture
- interacting
- interacting agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000052769 pathogen Species 0.000 title claims abstract description 158
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 149
- 238000001514 detection method Methods 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 52
- 239000012472 biological sample Substances 0.000 claims abstract description 162
- 239000003795 chemical substances by application Substances 0.000 claims description 160
- 230000001052 transient effect Effects 0.000 claims description 61
- 230000008859 change Effects 0.000 claims description 55
- 230000001332 colony forming effect Effects 0.000 claims description 44
- 238000012360 testing method Methods 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 15
- 230000003993 interaction Effects 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 208000002720 Malnutrition Diseases 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 4
- 230000003467 diminishing effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 4
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 230000004763 spore germination Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 241001515965 unidentified phage Species 0.000 claims description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims description 2
- 230000005611 electricity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract description 15
- 239000001963 growth medium Substances 0.000 description 48
- 239000000523 sample Substances 0.000 description 35
- 229930027917 kanamycin Natural products 0.000 description 20
- 229960000318 kanamycin Drugs 0.000 description 20
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 20
- 229930182823 kanamycin A Natural products 0.000 description 20
- 229920001817 Agar Polymers 0.000 description 18
- 239000008272 agar Substances 0.000 description 18
- 230000012010 growth Effects 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 14
- 238000013459 approach Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 241001646716 Escherichia coli K-12 Species 0.000 description 9
- 230000005669 field effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 7
- 229930182566 Gentamicin Natural products 0.000 description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 229960002518 gentamicin Drugs 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 6
- 239000004065 semiconductor Substances 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229960000268 spectinomycin Drugs 0.000 description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- -1 cyprofloxacin Chemical compound 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000002055 nanoplate Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009105 vegetative growth Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/403—Cells and electrode assemblies
- G01N27/414—Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
- G01N27/4145—Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS specially adapted for biomolecules, e.g. gate electrode with immobilised receptors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/403—Cells and electrode assemblies
- G01N27/414—Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
- G01N27/4146—Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS involving nanosized elements, e.g. nanotubes, nanowires
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48735—Investigating suspensions of cells, e.g. measuring microbe concentration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48785—Electrical and electronic details of measuring devices for physical analysis of liquid biological material not specific to a particular test method, e.g. user interface or power supply
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/046—Function or devices integrated in the closure
- B01L2300/047—Additional chamber, reservoir
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Electrochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Human Computer Interaction (AREA)
- Dispersion Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Nanotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
本出願は、2020年3月30日に出願された出願番号63/001,938の先願の米国仮出願の利益を主張し、その全体を参照により本明細書に組み込む。
本発明は、生体試料の検出と治療法の提案に関するもので、より詳細には、病原体検出のための方法、ならびに関連する治療法の開発および医師のための提案に関する。
20 センサ
30 病原体検出チップ
101 培養室
103 担体
105 検知チップ
105 感知チップ
107 培養培地
109 参照電極
110 リーダ
111 病原体試料
111L、111H 培養ウェル
112 病原体試料
112L、112H 培養ウェル
113 病原体試料
113L、113H 培養ウェル
200 半導体層
201 ソース
202 ドレイン
203 パッシベーション層
207 培養培地
207A 病原体
207B 相互作用剤
209 第1のゲート
209’ 第2のゲート
301 インキュベーションユニット
302 マイクロ流体構造
320 センサ
Claims (19)
- 以下を含む、病原体検出のための方法:
相互作用剤を含む培養室に生体試料を適用すること;
培養室内の生体試料に電気的に結合されたセンサを駆動すること;
センサからの電気信号を測定すること;および
電気信号に基づいて生体試料の病原体関係情報を取得すること。 - 前記センサからの前記電気信号を測定することは、所定の期間にわたってトランジスタのドレイン電流を測定することを含む、請求項1に記載の方法。
- 前記生体試料の病原体関係情報を取得することが、前記所定の期間中の前記ドレイン電流における少なくとも1つの一過性変化の存在を判定することを含む、請求項2に記載の方法。
- 前記所定の期間が約12時間未満である、請求項3に記載の方法。
- 前記生体試料を複数の培養室に適用することが、100μL当たり100未満のコロニー形成単位(CFU)を含有する前記生体試料を適用することを含む、請求項3に記載の方法。
- 前記一過性変化が、前記ドレイン電流において統計的に区別可能な信号である、請求項3に記載の方法。
- 前記相互作用剤が、胞子発芽を引き起こす薬剤、酸化的ストレスを引き起こす薬剤、化学的損傷または酵素破壊を引き起こす薬剤、栄養欠乏を引き起こす薬剤、UV照射、バクテリオファージ、抗生物質、必須イオン欠乏を引き起こす薬剤、酵素、放射線、または加熱を含む、請求項1に記載の方法。
- 前記培養室のうちの2つが、同一の相互作用剤を含み、異なる投与量または強度を有する、請求項7に記載の方法。
- 前記培養室のうちの2つが、異なる相互作用剤を含む、請求項7に記載の方法。
- 病原体関係情報が、病原体の存在、相互作用剤に対する病原体の感受性、病原体の耐性を誘導するのに充分な相互作用剤の投与量、病原体の活性を抑制するのに充分な相互作用剤の投与量、および病原体の指紋特性を含む、請求項1に記載の方法。
- 前記病原体の指紋特性が、病原体が、生きているか死亡んでいるか、活性であるか休眠しているか、伝染性であるか非伝染性であるか、または休眠、発芽、増殖、栄養、停滞、定常、または死亡を含む相のうちの1つにあることを含む、請求項10に記載の方法。
- 前記生体試料が、体液、血液、またはそれらの組み合わせを含む、請求項1に記載の方法。
- 少なくとも1つの一過性変化が電流中に存在する場合、さらに、単調増加する相互作用剤投与量の広がりテストを実施すること、または、異なる相互作用剤を適用して、生体試料中の病原体が相互作用剤のうちの1つに対して耐性であるかもしくは感受性であるかを判定することを含む、請求項3に記載の方法。
- 前記単調増加する相互作用剤投与量の広がりテストまたは前記単調減少する相互作用剤投与量の広がりテストが、それぞれ、前記相互作用剤のうちの1つの最小阻害濃度(MIC)の投与量を含む、請求項13に記載の方法。
- 一過性変化が電流中に存在しない場合、さらに、単調減少する相互作用剤投与量の広がりテストを実施すること、または、異なる相互作用剤を適用して、生体試料が病原体を含まないか、もしくは病原体が相互作用剤のうちの1つに感受性であるかどうかを判定することを含む、請求項3に記載の方法。
- 前記単調増加する相互作用剤投与量の広がりテストまたは前記単調減少する相互作用剤投与量の広がりテストが、それぞれ、前記相互作用剤のうちの1つの最小阻害濃度(MIC)の投与量を含む、請求項15に記載の方法。
- 以下を含む、病原体を検出するための方法:
生体試料を病原体検出チップに適用すること;ここで、前記チップは、前記生体試料を収容するように構成された培養室と、前記培養室に電気的に結合されたセンサと、前記センサから電気信号を取得するように構成されたリーダとを含む;
センサを駆動すること;および
リーダを介してセンサからの電気信号を測定し、電気信号に基づいて生体試料の病原体関係情報を取得すること。 - 前記生体試料を前記病原体検出チップに適用することが、前記生体試料を、前記培養室に電気的に結合された前記センサの固体表面に接触させることを含む、請求項17に記載の方法。
- 前記病原体検出チップが、さらに、前記培養室へまたは前記培養室内で前記生体試料を接種し、濃縮し、希釈し、または濾過するように構成されたマイクロ流体構造を含む、請求項17に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063001938P | 2020-03-30 | 2020-03-30 | |
US63/001,938 | 2020-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021168647A true JP2021168647A (ja) | 2021-10-28 |
Family
ID=75277863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021055249A Pending JP2021168647A (ja) | 2020-03-30 | 2021-03-29 | 病原体検出法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210302366A1 (ja) |
EP (1) | EP3889268A1 (ja) |
JP (1) | JP2021168647A (ja) |
KR (1) | KR20210122704A (ja) |
CN (1) | CN113466309A (ja) |
SG (1) | SG10202103157SA (ja) |
TW (1) | TWI792246B (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015503729A (ja) * | 2011-12-22 | 2015-02-02 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 感染性微生物の迅速な検出のための方法及び装置 |
JP2018527929A (ja) * | 2015-08-25 | 2018-09-27 | アバイルズ メディカル,インコーポレイテッド | 流体試料中の生存微生物を検出する装置、システムおよび方法 |
WO2019108859A1 (en) * | 2017-11-28 | 2019-06-06 | Inanobio, Inc. | Field effect transistor sensor detection assays and systems and methods of making and using same |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4528270A (en) * | 1982-11-02 | 1985-07-09 | Kabushiki Kaisya Advance Kaihatsu Kenkyujo | Electrochemical method for detection and classification of microbial cell |
GB8724845D0 (en) * | 1987-10-23 | 1987-11-25 | Metal Box Plc | Detecting microorganisms |
US20030022361A1 (en) * | 2001-02-22 | 2003-01-30 | Kenneth Houston | Smart culture vessel |
US20040033627A1 (en) * | 2002-05-31 | 2004-02-19 | The Regents Of The University Of California | Method and apparatus for detecting substances of interest |
JP4827144B2 (ja) * | 2005-06-14 | 2011-11-30 | ミツミ電機株式会社 | バイオセンサ装置 |
WO2008042003A2 (en) * | 2006-01-12 | 2008-04-10 | Biosense Technologies, Inc. | Method and composition for rapid viability testing of cells |
JP5228891B2 (ja) * | 2008-11-21 | 2013-07-03 | 株式会社リコー | センサデバイス |
CN101852765A (zh) * | 2010-05-06 | 2010-10-06 | 解宇 | 利用细菌的氧化反应判断其对药物敏感性的装置及方法 |
US8373206B2 (en) * | 2010-07-20 | 2013-02-12 | Nth Tech Corporation | Biosensor apparatuses and methods thereof |
JP5737655B2 (ja) * | 2011-07-13 | 2015-06-17 | 国立大学法人広島大学 | 半導体センサ |
CN102435653A (zh) * | 2011-09-05 | 2012-05-02 | 湖南大学 | 基于场效应晶体管的抗生素类药物筛选装置与方法 |
MX2017001448A (es) * | 2014-08-01 | 2018-01-12 | Uwm Res Foundation Inc | Deteccion de contaminantes del agua en tiempo real. |
DK3194373T3 (da) * | 2014-09-16 | 2021-04-26 | Univ Northeastern | Fremgangsmåde til monitorering af levedygtighed for en biofilm af pseudomonas aeruginosa baseret på elektrokemisk detektering af pyocyanin |
SG10201709799SA (en) * | 2016-11-29 | 2018-06-28 | Helios Bioelectronics Inc | Method for quantitatively profiling nucleic acids |
JP2019039734A (ja) * | 2017-08-24 | 2019-03-14 | 学校法人東北学院 | イオン・バイオセンサチップとイオン・バイオセンサモジュールおよびこれらを用いたイオン・バイオセンサ |
-
2021
- 2021-03-26 SG SG10202103157S patent/SG10202103157SA/en unknown
- 2021-03-29 TW TW110111308A patent/TWI792246B/zh active
- 2021-03-29 JP JP2021055249A patent/JP2021168647A/ja active Pending
- 2021-03-29 CN CN202110334809.8A patent/CN113466309A/zh active Pending
- 2021-03-29 EP EP21165591.5A patent/EP3889268A1/en active Pending
- 2021-03-29 US US17/215,376 patent/US20210302366A1/en active Pending
- 2021-03-30 KR KR1020210041058A patent/KR20210122704A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015503729A (ja) * | 2011-12-22 | 2015-02-02 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 感染性微生物の迅速な検出のための方法及び装置 |
JP2018527929A (ja) * | 2015-08-25 | 2018-09-27 | アバイルズ メディカル,インコーポレイテッド | 流体試料中の生存微生物を検出する装置、システムおよび方法 |
WO2019108859A1 (en) * | 2017-11-28 | 2019-06-06 | Inanobio, Inc. | Field effect transistor sensor detection assays and systems and methods of making and using same |
Non-Patent Citations (1)
Title |
---|
LAB ON A CHIP, vol. 17, JPN6022015988, 2017, pages 4283 - 4293, ISSN: 0004947966 * |
Also Published As
Publication number | Publication date |
---|---|
TWI792246B (zh) | 2023-02-11 |
EP3889268A1 (en) | 2021-10-06 |
SG10202103157SA (en) | 2021-10-28 |
CN113466309A (zh) | 2021-10-01 |
KR20210122704A (ko) | 2021-10-12 |
TW202144780A (zh) | 2021-12-01 |
US20210302366A1 (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muthukrishnan | Multidrug resistant tuberculosis–Diagnostic challenges and its conquering by nanotechnology approach–An overview | |
Baumann et al. | Microelectronic sensor system for microphysiological application on living cells | |
JP3933709B2 (ja) | ガスまたは蒸気の分析による状態検出方法 | |
ES2535836T3 (es) | Método y composición para un test rápido de viabilidad celular | |
US11913058B2 (en) | Devices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives | |
US10316348B2 (en) | Diagnostic system and process for rapid bacterial infection diagnosis | |
Strittmatter et al. | Analysis of intact bacteria using rapid evaporative ionisation mass spectrometry | |
Gahlaut et al. | Smartphone based dual mode in situ detection of viability of bacteria using Ag nanorods array | |
US20230022460A1 (en) | Amplifier System and Controls for Dielectrophoretic Tracking in Microfluidic Devices | |
Zhu et al. | Immuno‐affinity Amperometric Detection of Bacterial Infections | |
US10254245B2 (en) | Devices, systems and methods for detecting viable infectious agents in a fluid sample using an electrolyte-insulator-semiconductor sensor | |
JP6487919B2 (ja) | 病原菌用マトリクスによって強化された電気化学検出器 | |
Tanaka et al. | Detecting bacterial infections in wounds: a review of biosensors and wearable sensors in comparison with conventional laboratory methods | |
Koppenhöfer et al. | Monitoring nanoparticle induced cell death in H441 cells using field-effect transistors | |
CN107586823A (zh) | 基于拉曼光谱技术的碳青霉烯类药物敏感性的快速鉴定方法 | |
Younis et al. | Nanosensors for animal health monitoring | |
JP2021168647A (ja) | 病原体検出法 | |
CN101698879A (zh) | 检测细菌培养基电阻抗曲线形态的药物敏感试验方法 | |
Wu et al. | Cyclic AMP and biofilms reveal the synergistic proliferation strategy of Pseudomonas aeruginosa and Escherichia coli under the costimulation of high concentrations of microplastics and enrofloxacin | |
JP2004531718A (ja) | 揮発成分の感知による診断 | |
AU2002251318A1 (en) | Diagnosis by sensing volatile components | |
Abdullah et al. | Bacteria classification using electronic nose for diabetic wound monitoring | |
US20210130764A1 (en) | Method and apparatus of qr-coded, paper-based, colorimetric detection of volatile byproduct for rapid bacteria identification | |
Pont et al. | Analysis of volatile fingerprints for monitoring anti-fungal efficacy against the primary and opportunistic pathogen Aspergillus fumigatus | |
Parasuraman et al. | Standard Microbiological Techniques (Staining, Morphological and Cultural Characteristics, Biochemical Properties, and Serotyping) in the Detection of ESKAPE Pathogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210728 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230519 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230815 |